Remove 2025 Remove Complication Remove Individual Remove Manufacturing
article thumbnail

Degree of Weight Loss Affects Tirzepatide-Linked Cardiometabolic Risk Improvement

Physician's Weekly

TUESDAY, July 1, 2025 (HealthDay News) — For adults with obesity or overweight, tirzepatide-linked improvements in cardiometabolic risk factors are associated with the degree of weight reduction, according to a study published online June 24 in the Annals of Internal Medicine. Bruno Linetzky, M.D., Bruno Linetzky, M.D.,

article thumbnail

American Diabetes Association, June 20-23

Physician's Weekly

” The study was funded by MannKind, the manufacturer of Afrezza. This modality may be especially beneficial for individuals who face logistical, geographic, or personal barriers to participating in traditional DPPs, and could help expand access to diabetes prevention in underserved populations,” Mathioudakis said.